Investors

We are a clinical-stage pharmaceutical company seeking a strong investment 
Vapogenix is a clinical-stage company developing a novel class of non-opioid analgesics. The company's products are topically formulated volatile anesthetics, developed using the 505(b)(2) regulatory pathway and are patent-protected through 2034. Vapogenix has a robust pipeline in multiple clinical indications for this novel class of analgesics, including:
​
  • VPX638: Phase 2 for the treatment of acute and chronic wound pain (diabetic, venous and arterial ulcers, burns, etc.).
  • VPX595: Phase 2-ready for the treatment of acute procedure pain (lacerations, pre-IV or injection, dermatology and plastic surgery procedures, etc.).
  • VPX--: Preclinical program for the treatment of inflammatory pain (osteoarthritis, psoriasis, gout, sunburn, etc.).

In addition to analgesia, the data also reveals antimicrobial and anti-inflammatory action. Vapogenix's lead program, VPX638, has shown rapid onset of just 2-3 minutes, profound analgesia, long efficacy of 18 hours, and reduced opioid use by 40%. The anti-microbial and anti-inflammatory properties of VPX638 provide additional benefits.

Vapogenix is seeking a partner and funding to advance its portfolio programs. The company is well-positioned to succeed in the development of novel non-opioid analgesics and make a significant impact on the treatment of pain.

Here are some of the key benefits of investing in Vapogenix:
  • Large and growing market opportunity for pain therapies is estimated to be worth over $60 billion.
  • Novel and differentiated product candidates with a clear differentiation from existing therapies.
  • Strong management team with extensive experience in the pharmaceutical industry.
  • Proven track record of developing  innovative therapies.
If you are interested in learning more about Vapogenix, please visit our website or contact us at vapogenix@jmhconsult.com. We would be happy to answer any questions you have.